T M Kundig

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi Immunotherapy concepts under investigation
    T M Kundig
    Department of Dermatology, Zurich University Hospital, Zurich, Switzerland
    Allergy 66:60-2. 2011
  2. ncbi [Cancer immunotherapy--current status]
    T M Kundig
    Arbeitsgruppe für Experimentelle Immuntherapie, Zurich
    Ther Umsch 63:262-6. 2006
  3. ncbi Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults
    Thomas M Kundig
    University of Zurich, Department of Dermatology, University Hospital Zurich, Switzerland
    J Allergy Clin Immunol 117:1470-6. 2006
  4. ncbi Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial
    G Senti
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Clin Exp Allergy 39:562-70. 2009
  5. ncbi Intralymphatic immunization enhances DNA vaccination
    K J Maloy
    Department of Dermatology, and Institute of Experimental Immunology, Universitatsspital Zurich, Schmelzbergstrasse 12, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 98:3299-303. 2001
  6. ncbi Medication with antihistamines impairs allergen-specific immunotherapy in mice
    P Johansen
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Clin Exp Allergy 38:512-9. 2008
  7. ncbi Fibroblasts as efficient antigen-presenting cells in lymphoid organs
    T M Kundig
    Institute of Experimental Immunology, University of Zurich, Switzerland
    Science 268:1343-7. 1995
  8. ncbi Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy
    J M Martínez-Gómez
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Allergy 64:172-8. 2009
  9. ncbi The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy
    S von Moos
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Allergy 67:638-46. 2012
  10. ncbi Antimicrobial silk clothing in the treatment of atopic dermatitis proves comparable to topical corticosteroid treatment
    G Senti
    Unit for Experimental Immunotherapy, Department of Dermatology, University of Zurich, Zurich, Switzerland
    Dermatology 213:228-33. 2006

Collaborators

Detail Information

Publications15

  1. ncbi Immunotherapy concepts under investigation
    T M Kundig
    Department of Dermatology, Zurich University Hospital, Zurich, Switzerland
    Allergy 66:60-2. 2011
    ..Clinical trials show that TCIT, EPIT is safe and comparably effective to conventional immunotherapy. Implementation of these new methods would increase the spectrum of SIT options, allowing greater individual choice of SIT...
  2. ncbi [Cancer immunotherapy--current status]
    T M Kundig
    Arbeitsgruppe für Experimentelle Immuntherapie, Zurich
    Ther Umsch 63:262-6. 2006
    ..Although active immunotherapy is still in the experimental stage, the data are highly encouraging and it is expected that vaccination will soon become part of cancer management...
  3. ncbi Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults
    Thomas M Kundig
    University of Zurich, Department of Dermatology, University Hospital Zurich, Switzerland
    J Allergy Clin Immunol 117:1470-6. 2006
    ..In this study we covalently coupled a synthetic 16-amino-acid sequence of the allergen Der p 1 to a virus-like particle derived from the bacteriophage Qbeta (Qbeta-Der p 1)...
  4. ncbi Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial
    G Senti
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Clin Exp Allergy 39:562-70. 2009
    ..Therefore, the phase I/IIa study presented represents the first test of A-type CpGs in humans...
  5. ncbi Intralymphatic immunization enhances DNA vaccination
    K J Maloy
    Department of Dermatology, and Institute of Experimental Immunology, Universitatsspital Zurich, Schmelzbergstrasse 12, CH 8091 Zurich, Switzerland
    Proc Natl Acad Sci U S A 98:3299-303. 2001
    ..Because injection directly into a lymph node is a rapid and easy procedure in humans, these results have important clinical implications for DNA vaccination...
  6. ncbi Medication with antihistamines impairs allergen-specific immunotherapy in mice
    P Johansen
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Clin Exp Allergy 38:512-9. 2008
    ..Histamine released from activated mast cells and basophils is an important mediator in allergy. Therefore, antihistamines are efficiently and widely used to suppress allergic symptoms...
  7. ncbi Fibroblasts as efficient antigen-presenting cells in lymphoid organs
    T M Kundig
    Institute of Experimental Immunology, University of Zurich, Switzerland
    Science 268:1343-7. 1995
    ..Fibroblasts induced T cells only in the milieu of lymphoid organs. Thus, antigen localization affects self-nonself discrimination and cell-based vaccine strategies...
  8. ncbi Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy
    J M Martínez-Gómez
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Allergy 64:172-8. 2009
    ..The aim of this study was to test whether modified recombinant allergens can improve therapeutic efficacy in SIT while reducing allergic side-effects...
  9. ncbi The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy
    S von Moos
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    Allergy 67:638-46. 2012
    ..Such barrier function of the stratum corneum also hampers the use of common adjuvants used to enhance the efficacy of vaccination...
  10. ncbi Antimicrobial silk clothing in the treatment of atopic dermatitis proves comparable to topical corticosteroid treatment
    G Senti
    Unit for Experimental Immunotherapy, Department of Dermatology, University of Zurich, Zurich, Switzerland
    Dermatology 213:228-33. 2006
    ..Atopic dermatitis (AD) is aggravated by mechanical irritation and bacterial colonization...
  11. ncbi [HIV-1 vaccination--is there hope?]
    R F Speck
    Abteilung für Infektionskrankheiten und Spitalhygiene, Universitatsspital Zurich, Zurich
    Ther Umsch 62:695-702. 2005
    ..In this review we discuss the distinct aspects of the immune response, which could be exploited for HIV vaccine strategies and describe current vaccine approaches...
  12. ncbi [Allergen specific immunotherapy: new approaches]
    F Tay
    Clinical Trials Center, Zentrum für Klinische Forschung, Universitätsspital und Universität Zürich, Zurich
    Praxis (Bern 1994) 99:1279-84. 2010
    ..e. administration of allergens using a skin patch, are under investigation in clinical trials at the Zurich University Hospital...
  13. ncbi Analysis of the relationship between pollinosis and date of birth in Switzerland
    N Graf
    Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
    Int Arch Allergy Immunol 143:269-75. 2007
    ..The objective of this study was to examine the relationship between the month of birth and the development of birch and grass pollen allergy in the Swiss population...
  14. ncbi Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy
    P Johansen
    Unit for Experimental Immunotherapy, University Hospital of Zurich, Zurich, Switzerland
    Clin Exp Allergy 35:1591-8. 2005
    ..The major disadvantage of SIT is its low efficiency, requiring treatment over years...
  15. ncbi Immune responses in interleukin-2-deficient mice
    T M Kundig
    Institute of Experimental Immunology, University of Zurich, Switzerland
    Science 262:1059-61. 1993
    ..Natural killer cell activity was markedly reduced but inducible. These normal in vivo immune responses in IL-2-deficient mice question the importance of IL-2 as defined by in vitro studies...